-
Compositions and Methods for the Treatment and Diagnosis of Cancer
Publication number: 20110110925
Abstract: Compositions and methods for the diagnosis and treatment of cancer, particularly T-ALL, are disclosed.
Type: Application
Filed: November 19, 2010
Publication date: May 12, 2011
Applicants: Fox Chase Cancer Center, Dana Farber Cancer Institute
Inventors: David L. Wiest, Thomas A. Look
-
Pharmaceutical composition for cancer treatment containing gossypol and phenformin as active ingredients
Patent number: 10085950
Abstract: The present invention relates to a pharmaceutical composition for cancer treatment containing gossypol and phenformin as active ingredients. Specifically, the combinative treatment with gossypol and phenformin was verified to have a significantly higher anticancer activity than a single treatment with gossypol and phenformin alone. Therefore, the pharmaceutical composition of the present invention containing gossypol and phenformin having a synergetic anticancer activity can be favorably used for cancer treatment.
Type: Grant
Filed: February 26, 2015
Date of Patent: October 2, 2018
Assignee: National Cancer Center
Inventors: Soo Youl Kim, Jong Heon Kim, Young Ki Bae, Ho Lee, Hyon Chol Jang, Yong-Doo Choi, Kyeong Man Hong, Dong Wan Hong
-
Cancer treatment by combined inhibition of proteasome and telomerase activities
Publication number: 20100010064
Abstract: A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of a proteasome inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the proteasome inhibitor alone or the telomerase inhibitor alone. Preferably, efficacy is supraadditive or synergistic in nature relative to the combined effects of the individual agents, with minimal exacerbation of side effects.
Type: Application
Filed: April 14, 2006
Publication date: January 14, 2010
Applicants: Geron Corporation, Memorial Sloan-Kettering Cancer Center
Inventors: Malcolm A. S. Moore, Allison C. Chin
-
Cancer treatment by combined inhibition of proteasome and telomerase activities
Patent number: 7998938
Abstract: A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of a proteasome inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the proteasome inhibitor alone or the telomerase inhibitor alone. Preferably, efficacy is supraadditive or synergistic in nature relative to the combined effects of the individual agents, with minimal exacerbation of side effects.
Type: Grant
Filed: April 14, 2006
Date of Patent: August 16, 2011
Assignees: Geron Corporation, Memorial Sloan-Kettering Cancer Center
Inventors: Malcolm A.S. Moore, Allison C. Chin
-
3-(2-Hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer
Publication number: 20070112192
Abstract: Compounds of formula (IA) or (IB) or salts, N-oxides. hydrates or solvates thereof are Inhibitors of HSP90, and useful in the treatment of, for example, cancer: formula (IA), formula (IB) wherein Ar is an aryl or heteroaryl radical which is linked via a ring carbon, and which is substituted by a hydroxy group on a carbon in the 2-position, and which is otherwise either unsubstituted or optionally substituted; R1 is hydrogen or optionally substituted C1-C6 alkyl; R2 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C1-C6 alkyl, C1-C6alkenyl, or C1-C6 alkynyl; or a carboxyl, carboxamide or carboxyl ester group; and R3 is a carboxamide group.
Type: Application
Filed: December 4, 2003
Publication date: May 17, 2007
Applicants: VERNALIS (CAMBRIDGE) LIMITED, CANCER RESEARCH TECHNOLOGY LTD., THE INSTITUTE OF CANCER RESEARCH
Inventors: Mandy Beswick, Paul Brough, Martin Drysdale, Brian Dymock
-
3-(2-hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid amide derivatives as HSP90 inhibitors for the treatment of cancer
Patent number: 7803831
Abstract: Compounds of formula (IA) or (IB) or salts, N-oxides, hydrates or solvates thereof are Inhibitors of HSP90, and useful in the treatment of, for example, cancer: formula (IA), formula (IB) wherein Ar is an aryl or heteroaryl radical which is linked via a ring carbon, and which is substituted by a hydroxy group on a carbon in the 2-position, and which is otherwise either unsubstituted or optionally substituted; R1 is hydrogen or optionally substituted C1-C6 alkyl; R2 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C1-C6 alkyl, C1-C6alkenyl, or C1-C6 alkynyl; or a carboxyl, carboxamide or carboxyl ester group; and R3 is a carboxamide group.
Type: Grant
Filed: December 4, 2003
Date of Patent: September 28, 2010
Assignees: Vernalis (Cambridge) Limited, Cancer Research Technology Ltd., Institute Of Cancer Research
Inventors: Mandy Christine Beswick, Paul Andrew Brough, Martin James Drysdale, Brian William Dymock
-
Method and kits for identifying of CDK9 inhibitors for the treatment of cancer
Patent number: 10383873
Abstract: A method of determining sensitivity to cancer treatment includes the step of determining the presence of overexpression of MYC in a biological sample from a patient suffering from cancer, wherein the presence of overexpression of MYC indicates a sensitivity to a treatment by a CDK9 inhibitor and wherein the cancer is selected from the group consisting of carcinoma, leukemia, and lymphoma.
Type: Grant
Filed: April 2, 2015
Date of Patent: August 20, 2019
Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, ST. JUDE CHILDREN'S RESEARCH HOSPITAL
Inventors: Scott William Lowe, Charles J. Sherr, Chun-Hao Huang, Amaia Lujambio
-
Cancer imaging methods and cancer treatment methods using thermotherapy and drug delivery
Patent number: 11998765
Abstract: Cancer imaging methods and cancer treatment methods using thermotherapy and drug delivery are disclosed herein. In one embodiment, the temperature of heated tissue is determined from radio-frequency data from an ultrasound transducer based upon a change in backscattered energy of acoustic harmonics. In another embodiment, a plurality of nanocarriers containing an anti-tumor medication are administered to a patient, and are excited in a first non-thermal ultrasound mode and/or a second thermal ultrasound mode using an ultrasound source. In yet another embodiment, a plurality of nanoparticles are administered to a patient, then at least some of the nanoparticles are heated along with tissue at a site of a tumor, and a photoacoustic imaging unit is used to determine a temperature of the heated tissue at the site of the tumor.
Type: Grant
Filed: September 29, 2021
Date of Patent: June 4, 2024
Assignee: Cancer Rx, LLC
Inventors: Gholam A. Peyman, Michael Kolios, Celina Yang, Jahangir Tavakkoli, Elyas Shaswary, Hisham Assi, Joseph Carl Kumaradas
-
METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
Publication number: 20110256241
Abstract: The invention relates to compositions comprising an acid ceramidase inhibitor and a choline kinase inhibitor as well as to the uses thereof for the treatment of cancer. The invention also relates to methods for the selection of an individualised therapy of a cancer patient based on the detection of the acid ceramidase levels. Moreover, the invention also relates to compositions comprising a choline kinase inhibitor and a chemotherapeutic agent and uses thereof for the treatment of cancer. Finally, the invention also relates to compositions comprising a choline kinase inhibitor and a death receptor ligand and uses thereof for the treatment of cancer.
Type: Application
Filed: September 17, 2009
Publication date: October 20, 2011
Applicant: TRASLATIONAL CANCER DRUGS PHARMA, S.L.
Inventors: Ana Ramirez De Molina, Lourdes Garcia Oroz, Juan Carlos Lacal Sanjuan
-
Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment
Patent number: 11821042
Abstract: As described herein, chromosomal missegregations, chromosomal micronuclei, cytosolic DNA, and combinations thereof are indicative of metastatic cancer. Methods and compositions are described herein that are useful for detection and treatment of patients with chromosomal instabilities such as chromosomal missegregations, chromosomal micronuclei, cytosolic DNA, and combinations thereof. For example, some of the methods and compositions include use of kinesin-13 proteins such as Kif2b, MCAK/Kif2c, or KIF13A. The methods and compositions can also include inhibitors of STING, ENPP1, cGAS, NF-kB transcription factor p52, NF-kB transcription factor RelB, or any combination thereof. Methods are also described for identifying compounds that are effective for treatment of cancer, including metastatic cancer.
Type: Grant
Filed: July 10, 2018
Date of Patent: November 21, 2023
Assignees: Cornell University, Memorial Sloan-Kettering Cancer Center
Inventors: Lewis C. Cantley, Bryan Ngo, Samuel F. Bakhoum
-
METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
Publication number: 20100068302
Abstract: The invention relates to compositions comprising an acid ceramidase inhibitor and a choline kinase inhibitor as well as to the uses thereof for the treatment of cancer. The invention also relates to methods for the selection of an individualised therapy of a cancer patient based on the detection of the acid ceramidase levels. Moreover, the invention also relates to compositions comprising a choline kinase inhibitor and an alkylating agent and uses thereof for the treatment of cancer. Finally, the invention also relates to compositions comprising a choline kinase inhibitor and an alkylating agent or a death receptor ligand and uses thereof for the treatment of cancer.
Type: Application
Filed: December 8, 2008
Publication date: March 18, 2010
Applicant: TRASLATIONAL CANCER DRUGS PHARMA, S.L.
Inventors: Ana Ramirez De Molina, Lourdes Garcia Oroz, Juan Carlos Lacal Sanjuan
-
Biomarkers for cancer treatment
Patent number: 7812143
Abstract: The present invention provides identification of a thirty-five gene set that predicts the anticancer activity of inhibitors of the RAF/MEK/MAPK pathway, methods of qualifying cancer status in a subject, methods of identifying an anti-tumor response in a subject, methods of monitoring the efficacy of a therapeutic drug in a subject, and methods of identifying an agent useful in the treatment of a cancer based on expression of the thirty-five gene set.
Type: Grant
Filed: April 2, 2007
Date of Patent: October 12, 2010
Assignee: Memorial Sloan-Kettering Cancer Center
Inventors: Christine Pratilas, Neal Rosen
-
Synergistic cancer treatment
Patent number: 10792284
Abstract: The use of mitogen activated kinase inhibition therapy in combination with receptor tyrosine kinase therapy for the treatment of cancer is described.
Type: Grant
Filed: February 12, 2016
Date of Patent: October 6, 2020
Assignee: Memorial Sloan Kettering Cancer Center
Inventors: Scott W. Lowe, Neal Rosen, Eusebio Manchado-Robles, Susann Weissmueller
-
Pharmaceutical composition comprising aldehyde inhibitor and anticancer agent for treatment of brain cancer
Patent number: 11998543
Abstract: The present disclosure relates to a pharmaceutical composition for treating brain cancer containing an aldehyde inhibitor and an anticancer drug. Since there are many types of brain cancer and the boundary between brain cells and tumor cells in brain cancer is not clear, brain cancer is particularly difficult to treat. The pharmaceutical composition of the present disclosure may further contain a biguanide-based compound as needed, wherein the compound is preferably phenformin. The pharmaceutical composition of the present disclosure is very effective for the treatment and improvement of prognosis of brain cancer, and has remarkable effects of killing cancer cells and inhibiting cancer stem cell characteristics, compared to when each of the active ingredients is administered alone. Thus, it is expected that the pharmaceutical composition of the present disclosure will be widely used in the field of brain cancer treatment.
Type: Grant
Filed: May 17, 2019
Date of Patent: June 4, 2024
Assignees: Industry-Academic Cooperation Foundation, Yonsei University, National Cancer Center
Inventors: Seok-Gu Kang, Soo Youl Kim
-
METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
Publication number: 20120040021
Abstract: The invention relates to compositions comprising an acid ceramidase inhibitor and a choline kinase inhibitor as well as to the uses thereof for the treatment of cancer. The invention also relates to methods for the selection of an individualised therapy of a cancer patient based on the detection of the acid ceramidase levels. Moreover, the invention also relates to compositions comprising a choline kinase inhibitor and an alkylating agent and uses thereof for the treatment of cancer. Finally, the invention also relates to compositions comprising a choline kinase inhibitor and an alkylating agent or a death receptor ligand and uses thereof for the treatment of cancer.
Type: Application
Filed: August 12, 2011
Publication date: February 16, 2012
Applicant: TRASLATIONAL CANCER DRUGS PHARMA, S.L.
Inventors: Ana Ramirez De Molina, Lourdes Garcia Oroz, Juan Carlos Lacal Sanjuan
-
Cancer treatment with Go6976 and its related compounds
Publication number: 20020016352
Abstract: A chemotheraputic cancer treatment in which Gö6976 or a compound chemically similar to Gö6976 is administered to a mammal for the treatment of the cancer. The chemical compound is targeted to PKC &agr; activity. Experiments have shown Gö6976 and similar compounds to be effective for the treatment of breast cancer, leukemia, lung cancer, bone cancer, skin cancer, prostate cancer, liver cancer, brain tumor, cervical cancer, and cancers located in the digestive tract including gastric cancer and colorectal cancers. These treatments may be accomplished utilizing Gö6976 and compounds similar to it alone or in combination with prior art chemotherapy agents or with radiation therapy. In a preferred embodiment Gö6976 is used for the treatment of cancer as a preventative drug by preventing cancer cell formation.
Type: Application
Filed: July 24, 2001
Publication date: February 7, 2002
Inventors: Zhimin Lu, Keming Wang
-
Compositions and methods for the treatment of cancer
Patent number: 8597900
Abstract: Disclosed herein are methods and compositions for the treatment of cancer. In particular, the present invention discloses inhibitors of the Fanconi anemia pathway and methods using same. Such inhibitors are useful in inhibiting DNA damage repair and can be useful, for example, in the treatment of cancer.
Type: Grant
Filed: November 19, 2010
Date of Patent: December 3, 2013
Assignee: Dana-Farber Cancer Institute, Inc.
Inventors: Alan D. D'Andrea, Toshiyasu Taniguchi
-
Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease
Publication number: 20050038113
Abstract: The present invention relates to the use of the drug valproic acid and derivatives thereof as inhibitors of enzymes having histone deacetylase for the sensitizing treatment of human cancers in combination with established therapeutic principles. The invention also relates to the use of those compounds for the treatment of tumor metastasis and minimal residual disease. The invention includes the manufacture of a clinically used substance for the treatment of human cancers.
Type: Application
Filed: September 17, 2002
Publication date: February 17, 2005
Applicant: G2M Cancer Drugs AG
Inventors: Bernd Groner, Thorsten Heinzel, Bernd Hentsch, Winfried Wels, Peter Herrlich, Saverio Minucci, Pier Pelicci, Martin Gott Icher
-
ENHANCEMENT OF PROSTATE CANCER TREATMENT
Publication number: 20200095314
Abstract: The present invention provides a method of treatment of prostate cancer, comprising administering a therapeutically effective amount of an inhibitor of IL-23 and/or an inhibitor of IL-23R to a mammalian patient in need thereof. The prostate cancer may be castration resistant prostate cancer (CRPC). The inhibitor may, for example, be an anti-IL-23 antibody, such as risankizumab, guselkumab or tildrakizumab. The method of treatment may further comprise administration of androgen deprivation therapy, such as enzalutamide. Also provided is a method of predicting the development of resistance to androgen deprivation therapy (ADT) in a prostate cancer in a mammalian patient and a related screening method.
Type: Application
Filed: September 18, 2019
Publication date: March 26, 2020
Applicants: Fondazione per l'Istituto Oncologico di Ricerca (IOR), The Institute of Cancer Research: Royal Cancer Hospital
Inventors: Andrea Alimonti, Arianna Calcinotto, Johann de Bono
-
Materials and Methods for Treatment of Cancer
Publication number: 20080241825
Abstract: Glypican 5 is shown for the first time to have a role in proliferation of cancer cells, including tumours which do not show chromosomal amplification at 13q31. The use of glypican 5 (GPC5) antagonists and binding agents for the treatment of cancer, particularly rhabdomyosarcoma and breast cancer, is disclosed.
Type: Application
Filed: March 22, 2005
Publication date: October 2, 2008
Applicant: THE INSTITUTE OF CANCER RESEARCH ROYAL CANCER HOSPITAL
Inventors: Janet Shipley, Daniel Williamson, Jane Renshaw, Rosanne Orr
